Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the BCR::ABL1 fusion gene, producing a dysregulated tyrosine kinase enzyme and leading to uncontrolled production of myeloid cells in the bone marrow (BM) [1]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.